Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT01491100

16036

BF1101 (Other Identifier)

Details and patient eligibility

About

Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.

Enrollment: 1,085 patients

Sex: All

Ages: 12 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Relapsing Remitting Multiple Sclerosis (RRMS), and treated with Betaferon, with the decision for treatment made at the discretion of the attending physician, documented with a prescription of Betaferon by the physician
• EDSS 0 - 6
• Written informed consent

Exclusion criteria

• Patients who do not meet the local indication criteria for Betaferon treatment.
• Contraindications listed in the local SmPCs have to be considered.
• Patients with a history of severe head trauma.
• Patients with alcohol and/or drug abuse.
• Patients with mental retardation.
• Patients with learning disability.

Trial design

1,085 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta-1b (Betaseron, BAY86-5046)